Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel
Lauren Appell(University of Arkansas Medical Center), April Rahrig(Indiana University – Purdue University Indianapolis), Holly Pacenta(Children's Hospital Colorado), Erin Hall(Children's Mercy Hospital), Michael R. Verneris(NHS Blood and Transplant), Christa Krupski(Cincinnati Children's Hospital Medical Center), Margaret L. MacMillan(University of Minnesota Medical Center), Sunil S. Raikar(Emory University), Samuel John(Southwestern Medical Center), Gary Douglas Myers(Baylor College of Medicine), Vanessa A. Fabrizio(Children's Hospital Colorado), Muna Qayed(Emory University), Danielle Novetsky Friedman(National Coalition for Cancer Survivorship), Christen L. Ebens(University of Minnesota), Lena E. Winestone(University of California, San Francisco), Prakash Satwani(Pediatrics and Genetics), Christina Baggott(Palo Alto University), Stacy Cooper(Sidney Kimmel Comprehensive Cancer Center), Amy K. Keating(Boston Children's Hospital), Archana Ramgopal(University of Pittsburgh), Susanne H.C. Baumeister(Dana-Farber Cancer Institute), Snehit Prabhu(Stanford University), Jenna Rossoff(Lurie Children's Hospital), Nicole Karras(City Of Hope National Medical Center), Amy Moskop(Medical College of Wisconsin), Julie‐An Talano(Dana-Farber Cancer Institute), Theodore W. Laetsch(Children's Hospital of Philadelphia), Crystal L. Mackall(Parker Institute for Cancer Immunotherapy), Kevin J. Curran(Memorial Sloan Kettering Cancer Center), Khanh Nguyen(Stanford University), Rachel Phelan(Children's Hospital of Wisconsin), Alex Hoover(University of Minnesota Medical Center), Michelle L. Hermiston(VinUniversity), Christine L. Phillips(Cincinnati Children's Hospital Medical Center)
Cited by 0
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Comprehensive Analysis of Hypermutation in Human Cancer
|Cell|2017|795
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
|Transplantation and Cellular Therapy|2020|718
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
|Nature Medicine|2018|577